Close
Solutions
Online Inquiry

CONTACT US

USA:

UK:
Call us at:
USA:
UK:
Fax:
Email:

iPSC-derived CAR-NK Therapy Development

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The great success of chimeric antigen receptor (CAR)-T cells has prompted scientists to genetically modify human natural killer (NK) cells with CAR to better treat lethal cancer. NK cells can now be routinely produced from human pluripotent stem cells (PSC). These PSCs provide a novel resource that can be used to produce "off-the-shelf" NK cells with a homogeneous and standardized group for CAR-NK therapy.

At Creative Biolabs, we have developed the iPSC technology platform to produce NK cells derived from CAR-expressing stem cells. This technology platform provides an unlimited source of engineered stem cell-derived CAR-NK immune cells. These PSC-derived NK cells have similar phenotypes and functions to primary lymphocytes isolated from peripheral blood, thereby they can be precisely engineered to introduce the improved anti-tumor activity.

CRISPR/Cas9-based iPSC-NK Cell Editing Platform

We provide multiple strategies to engineer iPSC-derived NK (iPSC-NK) cells for enhanced functional potential, persistence, and homing. Examples of such gene editing strategies include (i) strategies aimed at introducing specificity through cleavage-resistant CD16 to combine with therapeutic antibodies or CAR; (ii) strategies aimed at improving the persistence of allogeneic iPSC-NK cells by making cells self-sufficient in terms of growth factors; (iii) strategies aimed at co-expressing CXCR3 to enhance the iPSC-NK cell homing to tumor cells.

More customized gene editing strategies can be performed according to your requirements.

Fig.1 The potential of iPSC-derived NK cells as a template for engineering. (Saetersmoen, 2019)

CAR-Stem Cell Platform for Manufacturing iPSC-NK Cells

One-Stop CAR-NK Therapy Development

iPSC-derived CAR-NK Therapy Development

HSC ENGINEERING

HSC from a healthy donor are engineered using viral vectors that insert the CAR sequence in the cell genome.

iPSC-derived CAR-NK Therapy Development

HSC DIFFERENTIATION

The CAR-HSC is stimulated by cytokines to differentiate into NK cells, resulting in a population of CAR-NK cells that can be used for multiple patients

iPSC-derived CAR-NK Therapy Development

TUMOR RECOGNITION AND KILLING

The CAR-NK cells infused in the patient selectively recognize the tumor cells expressing the antigen and mediate the killing.

As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NK therpy development, including but not limit to:

If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

Reference

  1. Saetersmoen, M. L., et al. (2019, January). Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. In Seminars in immunopathology (Vol. 41, No. 1, pp. 59-68). Springer Berlin Heidelberg.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates

Receive our latest news and insights.